SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved the ...

The injection is the first of its kind. Getty The U.S. Food and Drug Administration (FDA) has approved a medication for use in treating severe food allergies, and the agency says that this injection ...

XOLAIR is given in 1 or more injections under the skin (subcutaneous), 1 time every 2 or 4 weeks. In people with asthma, CRSwNP and food allergy, a blood test for a substance called IgE must be ...

Chances are, you may know a family living with food allergies. Food allergies are more prevalent than many realize, particularly among children in the United States. In 2024, an estimated 3.4 million ...

ATLANTA - If you have to be vigilant about what you eat, and keep an EpiPen close, Dr. Tom Chacko of Chacko Allergy, Asthma and Sinus Center, says the newly FDA-authorized allergy medication, Xolair, ...

That price equates to an aggregate equity value of $2.2 billion, according to GSK, who added that the upfront investment net ...

A new study finds that the asthma medication Xolair may substantially reduce severe allergic reactions in people who have multiple food allergies and are accidentally exposed to those foods. Data ...

CHICAGO (WLS) -- After the FDA approved a medication called Xolair to help lessen the severity of an accidental allergic reaction in people who are allergic to multiple foods, sufferers say they're ...

Findings showed 67% of the omalizumab group achieved the primary endpoint compared with 7% of the placebo group. Treatment with omalizumab, an anti-IgE antibody, significantly increased the amount of ...

SAN DIEGO -- Omalizumab (Xolair) injections outperformed oral immunotherapy (OIT) in increasing tolerance among children with multi-food allergy, largely because many patients couldn't tolerate OIT, ...

The FDA approved omalizumab-igec (Omlyclo) as the first biosimilar for omalizumab (Xolair) and the first for any respiratory condition in the U.S., drugmaker Celltrion announced Monday. The ...